AstraZeneca’s Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study

AstraZeneca’s Dato-DXd looks to have so far failed to add a ‘clinically meaningful’ benefit over chemo in the TROPION-Lung01 study, but analysts still expect success for the investigational antibody-drug conjugate.